STERIS assigns Pierre Boulud to key board committees
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K/A
Rhea-AI Filing Summary
STERIS plc reports that Director Pierre Boulud, whose election and the expansion of the Board from nine to ten members were previously disclosed, has received his initial committee assignments. Effective July 31, 2026, he was appointed to the Board’s Audit Committee and its Compliance and Technology Committee.
The company notes that no other changes were made to the matters previously reported regarding the Board’s composition or Mr. Boulud’s role.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Committee appointment effective date: July 31, 2026
Senior Notes Coupon: 2.700%
Senior Notes Coupon: 3.750%
3 metrics
Committee appointment effective date
July 31, 2026
Effective date for Pierre Boulud joining two Board committees
Senior Notes Coupon
2.700%
Coupon on Senior Notes due 2031 listed on New York Stock Exchange
Senior Notes Coupon
3.750%
Coupon on Senior Notes due 2051 listed on New York Stock Exchange
Key Terms
Audit Committee, Compliance and Technology Committee, Emerging growth company
3 terms
Audit Committee regulatory
"appointed to serve on the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Compliance and Technology Committee regulatory
"appointed to serve on the Audit Committee of the Board and the Compliance and Technology Committee"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does STERIS plc (STE) disclose in this 8-K/A about its Board?
STERIS plc discloses that Director Pierre Boulud has received initial Board committee assignments. Effective July 31, 2026, he joined the Audit Committee and the Compliance and Technology Committee, with no other changes to prior Board-related disclosures.
Which Board committees did Pierre Boulud join at STERIS plc (STE)?
Pierre Boulud was appointed to the STERIS plc Audit Committee and the Compliance and Technology Committee. These committee roles supplement his existing position as a Director, previously reported when the Board expanded from nine to ten members.
When did Pierre Boulud’s committee appointments at STERIS plc (STE) become effective?
His committee appointments became effective on July 31, 2026. On that date, he began serving on both the Audit Committee and the Compliance and Technology Committee, as part of his responsibilities as a Director of STERIS plc.
Did STERIS plc (STE) change any other Board matters in this amendment?
No. STERIS plc states that no other changes were made to the previously reported Board actions. The amendment is limited to disclosing Pierre Boulud’s initial committee assignments following his earlier election as a Director.
How had the STERIS plc (STE) Board composition changed before this 8-K/A?
Previously, the STERIS plc Board was increased from nine to ten members, and Pierre Boulud was elected as a Director. This amendment builds on that disclosure by specifying the Board committees on which he now serves.
AI-generated analysis. How Rhea-AI works. Not financial advice.
